title: [Attitude of the clinican toward adverse effects of protease inhibitors].
abstract: Since 1996, marketing of new drugs called protease inhibitors has revolutionized the treatment of patients suffering from AIDS. The side-effects of this new therapeutic family are quite well known but we wanted to evaluate the attitude of the clinician: can these adverse effects be corrected by symptomatic treatment, do they regress spontaneously or do they lead to an alternative PI therapy? We therefore carried out a retrospective survey in the Infectious Diseases Department of Poitiers Hospital consisting in research on files of patients (n = 70) treated in this department (hospitalization and consultation) for any clinical or biological abnormality attributable to the PI. For each drug we determined what sort of side-effects could be found and the position adopted by the clinician. For 30 patients the PI was stopped and for 21 of these cases because of drug toxicity (gastrointestinal, neurological, renal and metabolic effects). The biological anomalies are quite well tolerated and regress spontaneously in most cases.
authors.affiliation: Centre régional de pharmacovigilance, CHU, Pavillon Le Blaye, BP 577, 86021 Poitiers, France.
authors.forename: B
authors.initials: B
authors.lastname: Nicol
authors.forename: X
authors.initials: X
authors.lastname: Champagne
authors.forename: J P
authors.initials: JP
authors.lastname: Breux
authors.forename: T
authors.initials: T
authors.lastname: Pasdeloup
authors.forename: C
authors.initials: C
authors.lastname: Remblier
authors.forename: M C
authors.initials: MC
authors.lastname: Pérault
authors.forename: B
authors.initials: B
authors.lastname: Vandel
mesh_terms: D000328:Adult; D000368:Aged; D001291:Attitude of Health Personnel; D005260:Female; D005602:France; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006748:Hospital Departments; D006785:Hospitals, University; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000009:adverse effects; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D019888:Nelfinavir / Q000008:administration & dosage / Q000009:adverse effects; D009422:Nervous System Diseases / Q000139:chemically induced; D010820:Physicians / Q000523:psychology*; D012075:Remission, Spontaneous; D012189:Retrospective Studies; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects; D019258:Saquinavir / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D017320:HIV Protease Inhibitors; D019469:Indinavir; D019888:Nelfinavir; D019258:Saquinavir; D019438:Ritonavir
vernacular_title: Attitude du clinicien face aux effets indésirables des inhibiteurs des protéases.